Univariable Cox proportional hazard ratios for mortality for all subjects with pulmonary arterial hypertension
| Variable | HR (95% CI, p-value) | HR (95% CI, p-value) with variables scaled to log1.1 |
| Clinical characteristics | ||
| Age years | 1.02 (0.99–1.06, 0.17) | |
| Female sex | 1.18 (0.28–5.01, ns) | |
| Caucasian race | 0.21 (0.03–1.52, 0.12) | |
| NYHA FC III–IV | 1.11 (0.53–2.36, ns) | |
| 6MWD m | 1.00 (0.99–1.00, 0.08) | |
| Presence of CTD | 1.79 (0.79–4.05, 0.17) | |
| Haemodynamics | ||
| mPAP mmHg | 1.01 (0.98–1.04, ns) | |
| PAWP mmHg | 0.97 (0.88–1.07, ns) | |
| PVR Wood units | 1.06 (1.00–1.13, 0.06) | |
| CO L·min−1 | 0.72 (0.54–0.95, <0.05) | |
| Cardiac index L·min−1·m−2 | 0.70 (0.41–1.19, 0.18) | |
| LV metrics | ||
| LVESV mL | 0.97 (0.94–0.99, <0.05) | 0.90 (0.83–0.98, <0.05) |
| LVEDV mL | 0.98 (0.97–0.99, <0.01) | 0.88 (0.80–0.97, <0.05) |
| LVEDVI mL·m−2 | 0.98 (0.96–1.01, ns) | 0.95 (0.86–1.06, ns) |
| LVEDVI % predicted | 0.98 (0.97–1.00, 0.17) | 0.94 (0.85–1.06, 0.17) |
| LVEDMI g·m−2 | 1.02 (1.001–1.03, <0.05) | 1.15 (1.02–1.30, <0.05) |
| LVEDMI % predicted | 1.01 (1.001–1.03, <0.05) | 1.15 (1.02–1.30, <0.05) |
| RV metrics | ||
| RVEDVI mL·m−2 | 1.01 (0.99–1.02, ns) | 1.05 (0.93–1.17, ns) |
| RVEDVI % predicted | 1.00 (0.99–1.01, ns) | 1.07 (0.95–1.19, ns) |
| RVEF % | 0.98 (0.95–1.005, 0.11) | 0.93 (0.85–1.02, 0.11) |
| RVEF % predicted | 0.99 (0.98–1.01, ns) | 0.97 (0.88–1.06, ns) |
| RVESVI mL·m−2 | 1.01 (1.00–1.02, ns) | 1.05 (0.98–1.12, ns) |
| RVESVI % predicted | 1.00 (0.99–1.00, 0.06) | 1.06 (0.99–1.14, 0.06) |
| RVEDMI g·m−2 | 1.02 (1.01–1.04, <0.01) | 1.11 (1.04–1.19, <0.01) |
| RVEDMI % predicted | 1.01 (1.003–1.01, <0.01) | 1.12 (1.05–1.19, <0.01) |
| TAPSE mm | 0.93 (0.86–0.999, <0.05) | 0.93 (0.86–1.01, 0.07) |
| Composite metrics | ||
| VMI | 4.6 (1.44–14.7, <0.01) | 1.11 (1.03–1.19, <0.01) |
| SV/ESV | 0.24 (0.07–0.80, <0.05) | 0.93 (0.87–0.99, <0.05) |
| SV/PP | 0.65 (0.43–1.00, 0.05) | 0.93 (0.87–0.99, <0.05) |
HR: hazard ratio; NYHA FC: New York Heart Association functional class; 6MWD: 6-min walk distance; CTD: connective tissue disease; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; CO: cardiac output; LV: left ventricular; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVEDVI: left ventricular end-diastolic volume index; LVEDMI: left ventricular end-diastolic mass index; RV: right ventricular; RVEDVI: right ventricular end-diastolic volume index; RVEF: right ventricular ejection fraction; RVESVI: right ventricular end-systolic volume index; RVEDMI: right ventricular end-diastolic mass index; TAPSE: tricuspid annular plane systolic excursion; VMI: ventricular mass index; SV; stroke volume; ESV: end-systolic volume; PP: pulse pressure; ns: not significant (p>0.20).